IDEXX Laboratories Posts Strong Q2 Growth on Diagnostic Innovation
Event summary
- IDEXX Laboratories reported $1.217 billion in revenue for Q2 2026, up 10% year-over-year.
- Companion Animal Group (CAG) diagnostics recurring revenue grew 11%, driven by international expansion and premium instrument placements.
- Water segment revenues increased 15%, while Livestock, Poultry, and Dairy (LPD) saw an 11% rise.
- EPS reached $4.27, an 18% increase, supported by tax benefits and operational productivity.
The big picture
IDEXX Laboratories' Q2 results underscore the growing demand for advanced veterinary diagnostics, particularly in international markets. The company's focus on innovation, such as the IDEXX inVue Dx platform, is driving recurring revenue growth. With strong operational metrics and strategic investments in commercial capabilities, IDEXX is positioning itself to capitalize on long-term trends in pet healthcare.
What we're watching
- Premium Instrument Adoption
- The expansion of the IDEXX inVue Dx analyzer placements will drive recurring revenue growth.
- International Market Penetration
- CAG Diagnostics' 14% international growth signals potential for further global scaling.
- Operational Efficiency
- Sustained gross margin expansion hinges on continued productivity gains and pricing power.
Related topics